World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
82
Citations
29353
World Ranking
15963
National Ranking
8034

Primo N. Lara publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Primo N. Lara sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 587 publications — 70th percentile

70% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Primo N. Lara D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Primo N. Lara sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 82 D-Index — 21st percentile

21% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Primo N. Lara is affiliated with the University of California, Davis in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a focus on subfields including Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Cancer Research, and Surgery.

The scientist's scholarly output shows a strong emphasis on cancer-related topics, particularly in Prostate Cancer Treatment and Research, Renal Cell Carcinoma Treatment, Cancer Immunotherapy and Biomarkers, Bladder and Urothelial Cancer Treatments, Cancer Genomics and Diagnostics, Renal and Related Cancers, and Lung Cancer Treatments and Mutations.

Primo N. Lara has contributed to numerous research papers published across prominent venues. The most frequent publication venues include:

  • Journal of Clinical Oncology
  • Kidney Cancer
  • Annals of Oncology
  • Cancer Research
  • Clinical Lung Cancer

Recent notable papers authored or coauthored by Primo N. Lara comprise:

  • Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology, 2022, Journal of the National Comprehensive Cancer Network
  • The DNA methylation landscape of advanced prostate cancer, 2020, Nature Genetics
  • A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial, 2021, The Lancet
  • Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity, 2020, JCO Precision Oncology
  • Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors, 2020, Journal of Clinical Oncology

Collaborations are an integral part of this scientist's work. Frequent co-authors include:

  • Ian M. Thompson
  • Catherine M. Tangen
  • Mamta Parikh
  • David I. Quinn
  • Sumanta K. Pal

The substantial volume of publications in both clinical and molecular cancer research highlights the scientist's cross-disciplinary approach. The integration of studies related to immunotherapy, genomics, and targeted therapies reflects a comprehensive engagement with evolving cancer treatment paradigms.

Best Publications

  • Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

    Daniel P. Petrylak;Catherine M. Tangen;Maha H.A. Hussain;Primo N. Lara

  • Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

    David A. Quigley;Ha X. Dang;Shuang G. Zhao;Paul Lloyd

  • Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study

    Rahul Aggarwal;Jiaoti Huang;Joshi J. Alumkal;Li Zhang

  • Prospective Evaluation of Cancer Clinical Trial Accrual Patterns: Identifying Potential Barriers to Enrollment

    Primo N. Lara;Roger Higdon;Nelson Lim;Karen Kwan

  • Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124

    Primo N. Lara;Ronald Natale;John Crowley;Heinz Josef Lenz

  • Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

    David C. Smith;Matthew R. Smith;Christopher Sweeney;Aymen A. Elfiky

  • Consolidation Docetaxel After Concurrent Chemoradiotherapy in Stage IIIB Non–Small-Cell Lung Cancer: Phase II Southwest Oncology Group Study S9504

    David R. Gandara;Kari Chansky;Kathy S. Albain;Bryan R. Leigh

  • Trastuzumab, Paclitaxel, Carboplatin, and Gemcitabine in Advanced Human Epidermal Growth Factor Receptor-2/neu–Positive Urothelial Carcinoma: Results of a Multicenter Phase II National Cancer Institute Trial

    Maha H.A. Hussain;Gary R. MacVicar;Daniel P. Petrylak;Rodney L. Dunn

  • Aurora Kinases as Anticancer Drug Targets

    Oliver Gautschi;Jim Heighway;Philip C. Mack;Phillip R. Purnell

  • Twenty years post-NIH Revitalization Act: enhancing minority participation in clinical trials (EMPaCT): laying the groundwork for improving minority clinical trial accrual: renewing the case for enhancing minority participation in cancer clinical trials.

    Moon S. Chen;Primo N. Lara;Julie H. T. Dang;Debora A. Paterniti

  • Metabolic reprogramming in clear cell renal cell carcinoma

    Hiromi I. Wettersten;Omran Abu Aboud;Primo N. Lara;Robert H. Weiss

  • Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.

    Robert J. Motzer;Craig J. Nichols;Kim A. Margolin;Jennifer Bacik

  • A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma.

    Jonathan E. Rosenberg;Jonathan E. Rosenberg;Richard M. Bambury;Eliezer M. Van Allen;Eliezer M. Van Allen;Harry A. Drabkin

  • Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer

    Amir Goldkorn;Benjamin Ely;David I. Quinn;Catherine M. Tangen

  • Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer

    Primo N Lara;Jean Yves Douillard;Kazuhiko Nakagawa;Joachim Von Pawel

  • Evaluation of Prostate-Specific Antigen Declines for Surrogacy in Patients Treated on SWOG 99-16

    Daniel P. Petrylak;Donna Pauler Ankerst;Caroline S. Jiang;Catherine M. Tangen

  • Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer

    Tanya B. Dorff;Bryan Goldman;Jacek K. Pinski;Philip C. Mack

  • The DNA methylation landscape of advanced prostate cancer

    Shuang G. Zhao;Shuang G. Zhao;William S. Chen;William S. Chen;Haolong Li;Adam Foye

  • Japanese-US Common-Arm Analysis of Paclitaxel Plus Carboplatin in Advanced Non―Small-Cell Lung Cancer: A Model for Assessing Population-Related Pharmacogenomics

    David R. Gandara;Tomoya Kawaguchi;John Crowley;James Moon

  • Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: A Southwest Oncology Group Trial S0111

    Maha Hussain;Catherine M. Tangen;Primo N. Lara;Ulka N. Vaishampayan

Frequent Co-Authors

David R. Gandara
David R. Gandara University of California, Davis
David I. Quinn
David I. Quinn University of Southern California
Laurel A. Beckett
Laurel A. Beckett University of California, Davis
Catherine M. Tangen
Catherine M. Tangen Fred Hutchinson Cancer Research Center
Tomasz M. Beer
Tomasz M. Beer Oregon Health & Science University
Eric J. Small
Eric J. Small University of California, San Francisco
Maha Hussain
Maha Hussain Northwestern University
Martin E. Gleave
Martin E. Gleave University of British Columbia
Ian M. Thompson
Ian M. Thompson The University of Texas Health Science Center at San Antonio

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're exploring a future in Medicine but want flexible or alternative education options, a range of online degrees and career pathways are available. These programs can offer a faster, more affordable route into healthcare while allowing you to study at your own pace.

One growing area is health information management. With an online bachelor's in health information management, you can build a career at the intersection of healthcare, technology, and data analysis—a critical and evolving field.

For those interested in administrative roles, medical billing and coding online courses prepare you for essential behind-the-scenes work in hospitals, clinics, and insurance companies.

Nursing remains one of the most in-demand healthcare professions. You can launch your nursing career with a nursing degree online, or advance your education through the cheapest fnp programs to become a Family Nurse Practitioner.

Exploring these online degree options can open doors to rewarding and stable healthcare careers, often with lower tuition costs and greater flexibility than traditional campus-based programs.

Best Scientists Citing Primo N. Lara

Trending Scientists

Recently Published Articles